Pharma Two B Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharma Two B Ltd.
The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.
The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.
- Drug Delivery
- Generic Drugs
- Controlled Release